Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis.

[1]  S. Hutfless,et al.  Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[2]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[3]  M. Matsuura,et al.  Rapid induction of mucosal healing by intensive granulocyte and monocyte adsorptive aphaeresis in active ulcerative colitis patients without concomitant corticosteroid therapy , 2011, Alimentary pharmacology & therapeutics.

[4]  Takayuki Yamamoto,et al.  Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study , 2011, Journal of Gastroenterology.

[5]  T. Chiba,et al.  Effect and Safety of Granulocyte-Monocyte Adsorption Apheresis for Patients with Ulcerative Colitis Positive for Cytomegalovirus in Comparison with Immunosuppressants , 2011, Digestion.

[6]  Takayuki Yamamoto,et al.  Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: A prospective cohort study , 2010, Inflammatory bowel diseases.

[7]  T. Chiba,et al.  Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus , 2010, Journal of gastroenterology and hepatology.

[8]  S. Vavricka,et al.  Clinical trial: five or ten cycles of granulocyte–monocyte apheresis show equivalent efficacy and safety in ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.

[9]  T. Matsui,et al.  An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment , 2009, The American Journal of Gastroenterology.

[10]  S. Hanauer,et al.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. , 2009, Gastroenterology.

[11]  A. Mazzoni,et al.  Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12‐month follow up , 2008, Journal of gastroenterology and hepatology.

[12]  G. Parisi,et al.  Duration of remission and long‐term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[13]  T. Chiba,et al.  Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis , 2008, Alimentary pharmacology & therapeutics.

[14]  M. Kageoka,et al.  Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  H. Ogata,et al.  A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis , 2008, Journal of Gastroenterology.

[16]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[17]  A. Mazzoni,et al.  Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  F. Casellas,et al.  Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. , 2007, World journal of gastroenterology.

[19]  Mark Avigan,et al.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.

[20]  S. Hanauer,et al.  Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities , 2006, Inflammatory bowel diseases.

[21]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[22]  H. Koide,et al.  Effect of Granulocyte and Monocyte Adsorption Apheresis on Urinary Albumin Excretion and Plasma Endothelin-1 Concentration in Patients with Active Ulcerative Colitis , 2004, Blood Purification.

[23]  Tatsuo Tanaka,et al.  Adsorptive Granulocyte and Monocyte Apheresis versus Prednisolone in Patients with Corticosteroid-Dependent Moderately Severe Ulcerative Colitis , 2004, Digestion.

[24]  K. Davies,et al.  Expression of Fcγ and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis , 2004 .

[25]  A. Saniabadi,et al.  Studies on the Mechanisms of Leukocyte Adhesion to Cellulose Acetate Beads: An In Vitro Model to Assess the Efficacy of Cellulose Acetate Carrier‐based Granulocyte and Monocyte Adsorptive Apheresis , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[26]  I. Bjarnason,et al.  Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[27]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[28]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[29]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[30]  R. Fedorak,et al.  A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. , 1997, Gastroenterology.

[31]  W. Sandborn.  Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. , 1995, Gastroenterology.

[32]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[33]  G. Haber,et al.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories , 1987, Digestive Diseases and Sciences.

[34]  L. Melton,et al.  Prognosis of chronic ulcerative colitis in a community. , 1987, Gut.

[35]  P. Brunt,et al.  Nonspecific proctocolitis in northeastern Scotland: a community study. , 1983, Gastroenterology.

[36]  J. H. Baron,et al.  Out-patient Treatment of Ulcerative Colitis , 1962, British medical journal.

[37]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[38]  K. Davies,et al.  Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. , 2004, Rheumatology.

[39]  I. Bjarnason,et al.  Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  A. Munakata,et al.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study , 2001, Journal of clinical apheresis.

[41]  S. Targan,et al.  Role of cytokines in the pathogenesis of inflammatory bowel disease. , 2000, Annual review of medicine.

[42]  J. Hampe,et al.  Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. , 1999, Lancet.

[43]  L. G. Krovko.  [Complications of corticosteroid therapy]. , 1972, Klinicheskaia meditsina.

[44]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.